Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | USP8 | P40818 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12253692 | 0.67 | RAB9A (0.76) | RAB9ASMN1; SMN2NPC1ACHEKDM4E | |
| SCHEMBL10554849 | 0.66 | MEN1 (0.43) | RAB9ASMN1; SMN2KDM4ELMNAALDH1A1 | |
| SCHEMBL4226377 | 0.65 | RAB9A (0.57) | RAB9ASMN1; SMN2NPC1ACHEKDM4E | |
| SCHEMBL6157005 | 0.65 | RAB9A (0.53) | RAB9ASMN1; SMN2NPC1ACHEKDM4E | |
| SCHEMBL11807026 | 0.62 | ALDH1A1 (0.43) | RAB9ASMN1; SMN2NPC1ACHEKDM4E | |
| SCHEMBL3278153 | 0.61 | ALDH1A1 (0.60) | RAB9ASMN1; SMN2NPC1KDM4ELMNA | |
| SCHEMBL496978 | 0.61 | RAB9A (1.00) | RAB9ASMN1; SMN2NPC1KDM4ELMNA | |
| SCHEMBL7786089 | 0.61 | RAB9A (0.87) | RAB9ASMN1; SMN2NPC1KDM4ELMNA | |
| SCHEMBL7970824 | 0.61 | RAB9A (0.65) | RAB9ASMN1; SMN2NPC1ACHEKDM4E | |
| SCHEMBL9181274 | 0.60 | RAB9A (0.65) | RAB9ASMN1; SMN2NPC1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252569-B1 | ANTIINFECTIVE AND ANTITUMORAL COMPOUNDS ISOLATED FROM TROPICAL LIANAS | JULIUS MAXIMILIANS UNIVERSITÄT WÜRZBURG (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-8877718-B2 | Antiinfective and antitumoral compounds isolated from tropical lianas | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20110059911-A1 | Antiinfective and Antitumoral Compounds Isolated From Tropical Lianas | JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2252569-A2 | ANTIINFECTIVE AND ANTITUMORAL COMPOUNDS ISOLATED FROM TROPICAL LIANAS | Julius-Maximilians-Universität Würzburg (DE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009098082-A2 | ANTIINFECTIVE AND ANTITUMORAL COMPOUNDS ISOLATED FROM TROPICAL LIANAS | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059911-A1 | Antiinfective and Antitumoral Compounds Isolated From Tropical Lianas | NCL, SYNCRIP, MYC | RAB9A 559/4885SMN1; SMN2 3286/4885NPC1 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.